ArticleJournal of molecular histology2026
Syntaxin-4, a key exocytosis mediating protein, shows heterogeneous expression in insulin-positive cells of human donors with new-onset and longer duration of type 1 diabetes: comparison with non-diabetic autoantibody-positive and -negative donors.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Syntaxin-4, a beta cell plasma membrane-anchored protein, attaches to beta cell granules with two spatially-located nearby proteins, facilitating the fusion of beta cell-docked granules to the plasma membrane, followed by exocytotic release of insulin and remaining granule contents. During type 1 diabetes (T1D) and its preceding phase, it is unclear whether syntaxin-4 levels decline in residual beta cells, thereby contributing to impaired insulin release. The level of syntaxin-4 in insulin-positive regions of islets was determined following immunofluorescence staining of human pancreatic sections, with co-immunofluorescence staining for insulin and for glucagon by immunoperoxidase. Random islets from non-diabetic autoantibody-negative (Group 1; n = 7), non-diabetic autoantibody-positive (Group 2; n = 6), new-onset T1D (Group 3; n = 4) and long-term T1D (Group 4; n = 10) donors were quantified for syntaxin-4 levels. In groups 1 and 2, inter-islet staining intensities for syntaxin-4, although variable across individual donors, were similar overall between the groups, with lower intensities in group 3. In group 4, 3 donors with 0.58-1.5 years of T1D showed mean intensities comparable to groups 1 and 2, whereas donors with 4-7 years of T1D showed declining intensities. In general, the average syntaxin-4 intensities in the two diabetic groups were lower than those in the non-diabetic groups. The expression of syntaxin-4 in insulin-positive islet cells showed marked differences in intensity among most diabetic donors and autoantibody-positive and -negative non-diabetic donors. In some long-term diabetic donors, syntaxin-4 was also present in insulin- and glucagon-negative cells. During protracted T1D, reduced syntaxin-4 in islets may impair insulin release.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.